Dietary n-3 polyunsaturated fatty acids (n-3 PUFAs) have well-documented protective effects
against obesity-induced insulin resistance and hepatic steatosis. Here, we investigated the …

Patients with non-alcoholic fatty liver disease (NAFLD) have an increased risk for
progression to hepatocellular carcinoma in addition to comorbidities such as cardiovascular …

Parenteral nutrition (PN) is one of the basic therapies for patients with intestinal failure;
however, hepatic steatosis associated with PN limits the long-term use of PN. N-3 …

n‐3 polyunsaturated fatty acids (PUFAs) are beneficial for numerous models of liver
diseases. The probable protective effects of n‐3 PUFA against carbon‐tetrachloride‐(CCl4‐) …

High-fat and high-sugar (HFS) diets have been suggested to play a causal role in the
pathogenesis of non-alcoholic fatty liver disease (NAFLD). This study aimed to investigate …

Patients with non-alcoholic fatty liver disease are characterised by a decreased n-3/n-6
polyunsaturated fatty acid (PUFA) ratio in hepatic phospholipids. The metabolic …

Effective means for the prevention of alcohol‐induced liver disease, a global health problem,
have yet to be developed. We evaluated whether the high endogenous levels of omega‐3 …

The prevalence of non-alcoholic fatty liver disease (NAFLD) has increased in parallel with
central obesity and is now the most common chronic liver disease in developed countries …

Obesity is a recognized epidemic worldwide, and the accumulation of excess free saturated
fatty acids (SFAs) in cells induces cellular lipotoxic damage and increases the risk of a wide …

Background Polyunsaturated n-3 fatty acids (n-3 PUFAs) are reported to protect against high
fat diet-induced obesity and inflammation in adipose tissue. Here we aimed to investigate if …